(2)Commission Implementing Regulation (EU) 2021/52note extended the approval period of the active substances dimoxystrobin, mecoprop-P, metiram, oxamyl and pyraclostrobin until 31 January 2022, and the approval period of the active substances benfluralin, fluazinam, flutolanil and mepiquat until 28 February 2022.